PT  - JOURNAL ARTICLE
AU  - Flavio Moroni
AU  - Grazia Lombardi
AU  - Christian Thomsen
AU  - Patrizia Leonardi
AU  - Sabina Attucci
AU  - Fiamma Peruginelli
AU  - Serenella Albani Torregrossa
AU  - Domenico E. Pellegrini-Giampietro
AU  - Roberto Luneia
AU  - Roberto Pellicciari
TI  - Pharmacological Characterization of 1-Aminoindan-1,5-dicarboxylic Acid, a Potent mGluR1 Antagonist
DP  - 1997 May 01
TA  - Journal of Pharmacology and Experimental Therapeutics
PG  - 721--729
VI  - 281
IP  - 2
4099  - http://jpet.aspetjournals.org/content/281/2/721.short
4100  - http://jpet.aspetjournals.org/content/281/2/721.full
SO  - J Pharmacol Exp Ther1997 May 01; 281
AB  - We examined the pharmacological profile of 1-aminoindan-1,5-dicarboxylic acid (AIDA), a rigid (carboxyphenyl)glycine derivative acting on metabotropic glutamate receptors (mGluRs). In cells transfected with mGluR1a, AIDA competitively antagonized the stimulatory responses of glutamate and (1S,3R)-1-aminocyclopentane-1,3-dicarboxylic acid [(1S,3R)-ACPD] on phosphoinositide hydrolysis (pA 2 = 4.21). In cells transfected with mGluR5a, AIDA displayed a much weaker antagonist effect. In transfected cells expressing mGluR2, AIDA (≤1 mM) did not affect the inhibition of forskolin-stimulated adenylate cyclase activity induced by (1S,3R)-ACPD, but at large concentrations, it displayed a modest agonist activity. In rat hippocampal or striatal slices, AIDA (0.1–1 mM) reduced the effects of (1S,3R)-ACPD on phospholipase C but not on adenylate cyclase responses, whereas (+)-α-methyl-4-carboxyphenylglycine (0.3–1 mM) was an antagonist on both transduction systems. In addition, AIDA (0.3–1 mM) had no effect on mGluRs coupled to phospholipase D, whereas (+)-α-methyl-4-carboxyphenylglycine (0.5–1 mM) acted as an agonist with low intrinsic activity. In rat cortical slices, AIDA antagonized the stimulatory (mGluR1-mediated) effect of (1S,3R)-ACPD on the depolarization-induced outflow ofd-[3H]aspartate, disclosing an inhibitory effect ascribable to (1S,3R)-ACPD activating mGluR2 and/or mGluR4. Finally, mice treated with AIDA (0.1–10 nmol i.c.v.) had an increased pain threshold and difficulties in initiating a normal ambulatory behavior. Taken together, these data suggest that AIDA is a potent, selective and competitive mGluR1a antagonist. The American Society for Pharmacology and Experimental Therapeutics